Trial reportPharmacoEconomics2002
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
Trial report in PharmacoEconomics, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Devices for remote continuous monitoring of people with Parkinson's disease: a systematic review and cost-effectiveness analysis.Health technology assessment (Winchester, England) · 2024Pooled it
- Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: An Updated Methodological Review.PharmacoEconomics · 2023Pooled it
- The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease.Journal of neurology · 2014Trial
- Inhaled Levodopa for the Management of OFF Episodes in Parkinson's Disease: A Cost-Effectiveness Analysis.PharmacoEconomics · 2026Article
- The Cost-Effectiveness of Opicapone Versus Entacapone as Adjuvant Therapy for Levodopa-Treated Individuals With Parkinson's Disease Experiencing End-of-Dose Motor Fluctuations.Parkinson's disease · 2025Article
- Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health-Related Quality of Life.Movement disorders clinical practice · 2023Article
- The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.PharmacoEconomics · 2022Observational
- Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson's Disease: A Swedish Register-Based Study in 1823 Observations.PharmacoEconomics · 2021Article
- Cost-Effectiveness of Apomorphine Sublingual Film as an "On-Demand" Treatment for "OFF" Episodes in Patients with Parkinson's Disease.Journal of health economics and outcomes research · 2021Article
- The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease.Journal of market access & health policy · 2018Article
- Rasagiline and rapid symptomatic motor effect in Parkinson's disease: review of literature.Neurology and therapy · 2014Review
- Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.Drugs & aging · 2014Article
- Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.PharmacoEconomics · 2011Review
- The health-related, social, and economic consequences of parkinsonism: a controlled national study.Journal of neurology · 2011Article
- A review of the health-related quality of life and economic impact of Parkinson's disease.Drugs & aging · 2006Review
- Incorporation of uncertainty in health economic modelling studies.PharmacoEconomics · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the cost effectiveness of adjunctive therapy with entacapone versus standard treatment (levodopa) without entacapone for patients in the US with Parkinson's disease (PD) who experience 'off-time' (re-emergence of the symptoms of PD) while receiving levodopa. STUDY
designA Markov model was used to estimate 5-year costs and effectiveness of standard treatment with and without entacapone.
methodsProbabilities, unit costs, resource utilisation data and utilities were obtained from published literature, clinical trial reports, a national database, and clinical experts. PD disability was measured using the daily proportion of off-time and Hoehn and Yahr scale scores. The analysis measured costs from a societal and third-party payer perspective, and effectiveness as gains in quality-adjusted life-years (QALYs) and years without progression to >25% off-time.
resultsFrom a societal perspective, entacapone therapy resulted in an incremental cost of US dollars 9327 per QALY gained compared with standard treatment. Treatment with entacapone also provided an additional 7.6 months with < or =25% off-time/day compared with standard treatment. Sensitivity analyses indicated that the model is sensitive to changes in rates of improvement/deterioration of off-time, and to the number of doses per day of levodopa with adjunctive entacapone.
conclusionsThe addition of entacapone to standard treatment for patients receiving levodopa who experience off-time provides additional QALYs and gain in time with minimal fluctuations. Results of this modelling exercise suggest that therapy with entacapone may be cost effective when compared with standard treatment for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.